Apolipoprotein-E-deficient mice exhibit an increased susceptibility to disseminated candidiasis

Medical Mycology

Volumn 42, Issue 4, 2004, Pages 341-348

  Vonk, Alieke G ^a   De Bont, Natasja ^a   Netea, Mihai G ^a   Demacker, Pierre N M ^a   Van Der Meer, Jos W M ^a   Stalenhoef, Anton F H ^a   Kullberg, Bart Jan ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Apolipoprotein; Candida albicans; Candidiasis

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; CULTURE MEDIUM; FUNGUS CULTURE; FUNGUS GROWTH; GROWTH INHIBITION; HOST RESISTANCE; HYPERLIPOPROTEINEMIA; INFECTION SENSITIVITY; KIDNEY HOMOGENATE; LIPOPROTEIN BLOOD LEVEL; MORTALITY; MOUSE; NONHUMAN; NUTRIENT; PROTEIN DEPLETION;

ANIMALS; APOLIPOPROTEINS E; CANDIDA ALBICANS; CANDIDIASIS; FUNGEMIA; GENETIC PREDISPOSITION TO DISEASE; HYPERLIPOPROTEINEMIAS; LIPOPROTEINS, VLDL; MICE; MICE, INBRED C57BL;

CANDIDA; CANDIDA ALBICANS;

EID: 4444372754     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/13693780410001657135     Document Type: Article

References (29)

1. Rex JH, Bennett JE, Sugar AM, Pappas PG, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331: 1325-1330.
2. Fraser VJ, Jones M, Dunkel J, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15: 414-421.
3. D'Angio R, Quercia RA, Treiber NK, McLaughlin JC, Klimek JJ. The growth of microorganisms in total parenteral nutrition admixtures. J Parenter Enteral Nutr 1987; 11: 394-397.
4. Mershon J, Nogami W, Williams JM, Yoder C, Eitzen HE, Lemons JA. Bacterial/fungal growth in a combined parenteral nutrition solution. J Parenter Enteral Nutr 1986; 10: 498-502.
5. Netea MG, Demacker PN, De Bont N, et al. Hyperlipoproteinemia enhances susceptibility to acute disseminated Candida albicans infection in low-density- lipoprotein-receptor-deficient mice. Infect Immun 1997; 65: 2663-2667.
6. Netea MG, Curfs JH, Demacker PN, Meis JF, van der Meer JW, Kullberg BJ. Infusion of lipoproteins into volunteers enhances the growth of Candida albicans. Clin Infect Dis 1999; 28: 1148-1151.
7. Mistry MJ, Clay MA, Kelly ME, Steiner MA, Harmony JA. Apolipoprotein E restricts interleukin-dependent T lymphocyte proliferation at the G1A/G1B boundary. Cell Immunol 1995; 160: 14-23.
8. Kelly ME, Clay MA, Mistry MJ, Hsieh Li HM, Harmony JA. Apolipoprotein E inhibition of proliferation of mitogen- activated T lymphocytes: production of interleukin 2 with reduced biological activity. Cell Immunol 1994; 159: 124-139.
9. Terkeltaub RA, Dyer C A, Martin J, Curtiss LK. Apolipoprotein (apo) E inhibits the capacity of monosodium urate crystals to stimulate neutrophils. Characterization of intra-articular apo E and demonstration of apo E binding to urate crystals in vivo. J Clin Invest 1991; 87: 20-26.
10. Pepe MG, Curtiss LK. Apolipoprotein E is a biologically active constituent of the normal immunoregulatory lipoprotein, LDL-In. J Immunol 1986; 136: 3716-3723.
11. Roselaar SE, Daugherty A. Apolipoprotein E-deficient mice have impaired innate immune responses to Listeria monocytogenes in vivo. J Lipid Res 1998; 39: 1740-1743.
12. de Bont N, Netea MG, Demacker PN, et al. Apolipoprotein E knock-out mice are highly susceptible to endotoxemia and Klebsiella pneumoniae infection. J Lipid Res 1999; 40: 680-685.
13. de Bont N, Netea MG, Demacker PN, Kullberg BJ, van der Meer JW, Stalenhoef AF. Apolipoprotein E-deficient mice have an impaired immune response to Klebsiella pneumoniae. Eur J Clin Invest 2000; 30: 818-822.
14. Van Oosten M, Rensen PC, Van Amersfoort ES, et al. Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat gram-negative sepsis. J Biol Chem 2001; 276: 8820-8824.
15. van Ree JH, van den Broek WJ, Dahlmans VE, et al. Diet-induced hypercholesterolemia and atherosclerosis in heterozygous apolipoprotein E-deficient mice. Atherosclerosis 1994; 111: 25-37.
16. Kullberg BJ, van't Wout JW, van Furth R. Role of granulocytes in increased host resistance to Candida albicans induced by recombinant interleukin-1. Infect Immun 1990; 58: 3319-3324.
17. Vogels MT, Mensink EJ, Ye K, et al. Differential gene expression for IL-1 receptor antagonist, IL-1, and TNF receptors and IL-1 and TNF synthesis may explain IL-1-induced resistance to infection. J Immunol 1994; 153: 5772-5780.
18. Vonk AG, Wieland CW, Netea MG, Kullberg BJ. Phagocytosis and intracellular killing of Candida albicans blastoconidia by neutrophils and macrophages: a comparison of different microbiological test systems. J Microbiol Methods 2002; 49: 55-62.
19. Gaviria JM, van Burik JA, Dale DC, Root RK, Liles WC. Modulation of neutrophil-mediated activity against the pseudohyphal form of Candida albicans by granulocyte colony- stimulating factor (G-CSF) administered in vivo. J Infect Dis 1999; 179: 1301-1304.
20. Lundqvist H, Dahlgren C. Isoluminol-enhanced chemiluminescence: a sensitive method to study the release of superoxide anion from human neutrophils. Free Radic Biol Med 1996; 20: 785-792.
21. Demacker PN, van Sommeren-Zondag DF, Stalenhoef AF, Stuyt PM, van't Laar A. Ultracentrifugation in swinging-bucket and fixed-angle rotors evaluated for isolation and determination of high-density lipoprotein subfractions HDL2 and HDL3. Clin Chem 1983; 29: 656-663.
22. Murthy AR, Lehrer RI. Harwig SS, Miyasaki KT. In vitro candidastatic properties of the human neutrophil calprotectin complex. J Immunol 1993; 151: 6291-6301.
23. Payne CD, Ray TL, Downing DT. Cholesterol sulfate protects Candida albicans from inhibition by sphingosine in vitro. J Invest Dermatol 1996; 106: 549-552.
24. Yeaman MR, Ibrahim AS, Edwards Jr. JE, Bayer AS, Ghannoum MA. Thrombin-induced rabbit platelet microbicidal protein is fungicidal in vitro. Antimicrob Agents Chemother 1993; 37: 546-553.
25. Casadevall A. Antibody immunity and invasive fungal infections. Infect Immun 1995; 63: 4211-4218.
26. Hasenclever HF. The in vitro interactions of Candida albicans with nonspecific serum proteins. Mycopathologia 1978; 65: 169-176.
27. Leunk RD, Moon RJ. Physiological and metabolic alterations accompanying systemic candidiasis in mice. Infect Immun 1979; 26: 1035-1041.
28. Wanten GJ, Curfs JH, Meis JF, Naber AH. Phagocytosis and killing of Candida albicans by human neutrophils after exposure to structurally different lipid emulsions. J Parenter Enteral Nutr 2001; 25: 9-13.
29. Laskowitz DT, Lee DM, Schmechel D, Staats HF. Altered immune responses in apolipoprotein E-deficient mice. J Lipid Res 2000; 41: 613-620.